Extension of one year invokes a $1-million payment to Idera.
Novartis extended the the research phase of its collaboration with Idera Pharmaceuticals, which begain in June, 2005, by one year.
Idera will receive a $1 million upfront, and Novartis will continue to fund research.
Idera’s agreements with Novartis are structured in two phases. During the research phase, Idera and Novartis are working to evaluate TLR9 agonists. Novartis may select candidates for further development through human clinical proof-of-concept trials. It may then elect to implement the next phase to complete the development and commercialize one or more of the TLR9 agonist candidates in the fields of asthma and allergy.